Epitalon Nasal Spray: Evidence, Formulation, and Research Questions

Epitalon nasal spray refers to the nasal administration of Epitalon (Epithalon; AEDG, Ala-Glu-Asp-Gly) via the nasal cavity, but published evidence is limited mostly to rat studies rather than controlled human trials. Nasal Epitalon produced measurable neural and pineal responses in animals, but human bioavailability, optimal formulation, delivered dose, and route-specific safety remain unestablished. [1–3]

Search interest in the term Epitalon nasal spray is often based on the assumption that the nasal route is already well characterized clinically. The scientific literature does not support this.

The strongest direct evidence comes from a small group of preclinical studies in which intranasal Epitalon was administered to rats. These experiments analyzed the activity of cerebral cortex neurons and pineal gland responses under stress conditions. They show that intranasal exposure can induce measurable biological effects in an animal model, but they do not establish human pharmacokinetics, absolute bioavailability, brain concentration, clinical efficacy, or an evidence-based protocol for using the spray. [1–3]

The nasal spray also encompasses two distinct scientific elements: the active substance and the delivery system. Even if two products contain nominally the same amount of Epitalon, they can deliver different amounts to the nasal mucosa because they may differ in concentration, volume released by the pump, droplet size, spray pattern, formulation viscosity, pH, preservatives, and applicator design. FDA guidelines for nasal products account precisely for this relationship between the formulation and the device.

What is Epitalon Nasal Spray?

Epitalon nasal spray is a formulation designed to deliver the AEDG tetrapeptide via the nasal cavity instead of through injection or ingestion. Published research on Epitalon used the intranasal route in rats, but has not demonstrated a standardized spray formulation for humans, a clinically validated dose per spray, or established nasal bioavailability. [1–3]

The term nasal administration means placing a substance in the nasal cavity, where it can come into contact with the nasal mucosa.

The nasal mucosa is highly vascularized, making it an attractive route for local or systemic drug delivery. For certain compounds, researchers are also analyzing the possibility of facilitating access to the central nervous system via pathways associated with the olfactory region and the trigeminal nerve.

That was precisely the starting point of classical neurophysiological research on Epitalon.

Sibarov and coworkers described the intranasal route as a non-invasive administration chosen to facilitate the delivery of Epitalon to the central nervous system. In urethane-anesthetized male Wistar rats, the extracellular activity of cortical neurons was recorded following intranasal exposure to Epitalon. [1]

A related Russian-language publication by the same research group also described the modulation of cerebral cortex neuronal activity following intranasal administration of Epitalon. [2]

In another study on rats, intranasal Epitalon was used during the analysis of C-Fos expression in the pineal gland and structural changes induced by osmotic stress. [3]

These experiments confirm that nasal Epitalon was investigated experimentally.

They do not prove, however, that commercially available nasal sprays replicate the same formulation, concentration, deposition pattern, systemic exposure, or central nervous system exposure.

A broader comparison of administration routes can be found in the article Epitalon Injection and Administration Routes in Research.

Was intranasal Epitalon studied in humans?

There are no robust, controlled human studies establishing the pharmacokinetics, bioavailability, clinical efficacy, or safety of intranasal Epitalon. Direct literature regarding this route consists primarily of studies in rats, so animal findings should not be interpreted as evidence of predictable systemic or central nervous system exposure in humans. [1–3]

This is the most significant limitation on the evidence.

Published rat studies show biological responses following nasal exposure, but do not answer questions relevant to human application.

They do not determine, among other things:

• what portion of an intranasal dose is absorbed into the systemic circulation;
• what concentration of intact AEDG is achieved in human plasma;
• what is the time to reach maximum concentration;
• what part remains in the nasal cavity and what part goes into the alimentary tract after swallowing;
• what concentrations are reached in the brain or cerebrospinal fluid;
• what does the pharmacokinetics look like after repeated administration;
• how is the exposure of the nasal mucosa tolerated;
• are there clinical effects regarding sleep, cognitive function, longevity, or the endocrine system.

In a 2007 study of the rat cerebral cortex, changes in neuronal activity were recorded shortly after intranasal administration. [1]

This was an acute electrophysiological endpoint in anesthetized rats, rather than evidence of therapeutic benefit or quantified brain delivery in humans.

Similarly, an experiment on pineal stress showed changes in C-Fos expression and a partial reduction in stress-related structural changes in the pineal tissue of rats. [3]

This is also preclinical physiology.

Statements such as „Epitalon nasal spray crosses the blood–brain barrier in humans,” „nasal Epitalon is rapidly absorbed in humans,” or „nasal Epitalon has a higher bioavailability than injection” therefore require direct pharmacokinetic data in humans, which is currently lacking.

How is Nasal Administration Different from an Injection?

Nasal and injectable Epitalon differ in the way the peptide reaches the tissues. Nasal administration relies on formulation deposition and absorption through the nasal mucosa, whereas subcutaneous or intramuscular injection bypasses the barriers of the nose and gastrointestinal tract. However, there is no robust human study directly comparing the pharmacokinetics or efficacy of these routes.

Injection and nasal administration are fundamentally different exposure systems.

Injection

Subcutaneous administration has a much larger body of historical research on Epitalon, particularly in rodent studies on aging, lifespan, and cancer.

Injection bypasses both gastrointestinal digestion and the nasal mucosa. The administered peptide still needs to be absorbed from the injection site, but its amount does not depend on spray plume geometry or nasal cavity deposition.

Nasal Catheter

The nasal spray must first deposit the formulation in the appropriate area of the nasal cavity.

Subsequently, several processes may occur. The material may remain locally on the mucous membrane, be absorbed into the systemic circulation, be removed by mucociliary transport, be swallowed and enter the gastrointestinal tract, or potentially interact with pathways leading to the central nervous system.

How much of the material follows each of these paths depends on the formulation and the characteristics of the device.

Broader studies on nasal products show that the spray angle, droplet size, formulation properties, and application geometry can significantly alter the deposition site of the material in the nasal cavity. [4]

The FDA also treats the nasal spray formulation and pump as interdependent elements when evaluating product quality and bioavailability or bioequivalence.

Therefore, the nominal statement „1 mg intranasally” cannot be automatically compared to „1 mg by injection,” as if both routes led to identical biological exposure.

No validated conversion factor has been established between these routes of administration in humans for Epitalon.

What Determines the Amount of Epitalon Delivered by the Spray?

The amount delivered by the Epitalon nasal spray depends on the peptide concentration, the volume of liquid released per actuation, the repeatability of the pump's operation, its priming status, the viscosity of the formulation, the spray pattern, droplet size, and the design of the device. Therefore, the concentration in the bottle alone does not determine the amount of peptide that reaches the nasal mucosa per spray.

One spray means a single activation of the pump mechanism.

In the case of a metered nasal product, the theoretical amount of peptide released per actuation depends on two fundamental values: the concentration of the peptide in the solution and the volume of liquid expelled by the pump.

However, the actual performance of the product is more complex than simple arithmetic alone.

FDA guidelines for nasal sprays indicate numerous quality attributes that can affect the delivered dose and product performance, including pump parameters, content uniformity of the spray, spray pattern, plume geometry, droplet size distribution, formulation composition, and container-closure system properties.

Independent studies on nasal formulation deposition also show that droplet size, spray characteristics, and application angle can influence the deposition site of the material in the nasal cavity. [4]

For a nasal product with Epitalon, a scientifically useful specification should therefore contain more information than just the total amount of peptide in the bottle.

Important parameters include:

• total peptide concentration;
• verified volume delivered per actuation;
• dose uniformity;
• the number of validated sprays;
• pump preparation requirements;
• droplet size distribution;
• spray pattern and stream geometry;
• pH and viscosity of the formulation;
• peptide stability over the declared period of use.

Without such data, claims such as „each spray delivers exactly X micrograms” should be treated as product-specific manufacturer declarations rather than independently established Epitalon pharmacology.

What are the challenges of nasal formulation stability?

The nasal formulation of Epitalon must maintain peptide identity, concentration, chemical stability, microbiological quality, and consistent spray performance during storage and repeated use. Aqueous formulations may be susceptible to degradation, contamination, adsorption, aggregation, pH shifts, the effects of preservatives, and changes in pump performance, while stability data for nasal Epitalon remain limited.

A nasal spray is more complex than simply dissolving the peptide in water and putting the solution in a pump bottle.

The peptide must maintain its chemical integrity throughout the declared storage and use period.

The formulation must also deliver a repeatable amount with each run.

Several categories of stability matter.

Chemical stability

The concentration of AEDG may theoretically change due to degradation or interaction with formulation components.

The current peer-reviewed literature regarding Epitalon does not define a universal period of aqueous stability for the nasal formulation.

Therefore, statements such as „Epitalon nasal spray remains stable for 30 days” require analytical testing of a specific product rather than extrapolation from general peptide storage principles.

Microbiological stability

Repeated opening and operation of the device can create a potential contamination pathway.

A multi-dose nasal product may therefore require a preservative system or a packaging design capable of maintaining microbiological quality for the stated period of use.

A preservative can limit the growth of microorganisms, but it does not automatically prevent peptide degradation.

Physical Stability

Aggregation, precipitation, adsorption to the surface of the bottle or pump, and viscosity changes can alter the amount delivered upon application.

FDA guidelines for nasal sprays emphasize the importance of the container-closure system, pump performance, particle or droplet size distribution, and dose uniformity as elements of product quality.

Device Stability

The pump itself can change its performance over time.

Changes in the applicator function can affect volume, spray pattern, or deposition, even if the peptide concentration in the bottle remains unchanged.

Therefore, formulation stability and device performance stability should be evaluated together.

Broader stability guidelines are discussed in the article Epitalon Reconstitution, Storage and Stability for Laboratory Research.

Is N-Acetyl Epitalon Spray the Same as Epitalon?

No. N-acetyl Epitalon is chemically modified at the N-terminus and should not be treated as identical to unmodified Epitalon, which is AEDG. PubChem identifies N-acetyl Epitalon as Ac-Ala-Glu-Asp-Gly-OH with a different chemical formula and molecular weight, and clinical or pharmacokinetic data regarding one form cannot automatically confirm the other.

Unmodified Epitalon is typically presented as:

H-Ala-Glu-Asp-Gly-OH

N-acetyl Epitalon is presented as:

Ac-Ala-Glu-Asp-Gly-OH

This N-terminal acetyl group modifies the molecule.

PubChem gives the molecular formula C16H24N4O10 and a molecular weight of approximately 432.38 g/mol for N-acetyl Epitalon. The FDA substance registry also lists N-acetyl Epitalon as a distinct verified chemical substance with the UNII identifier UXR7AF6R4F.

This distinction is important because chemical modification can affect properties such as susceptibility to enzymes, charge distribution, solubility, receptor interactions, membrane transport, or pharmacokinetics.

However, such potential effects must be measured.

The fact that N-acetylation can theoretically affect stability does not prove that N-acetyl Epitalon has better nasal bioavailability, a longer half-life, greater penetration into the central nervous system, or greater efficacy.

An additional terminological problem appears in online products: N-acetyl Epitalon and N-acetyl Epitalon amidate are sometimes presented as if they were interchangeable.

They do not have to be the same structure.

N-acetyl Epitalon in the free acid form is Ac-AEDG-OH, whereas the amidated derivative additionally modifies the C-terminal end to Ac-AEDG-NH2. The latter form is therefore a doubly modified analogue.

The distinction should be confirmed on the basis of analytical documentation, and not just the product name.

Most importantly, the classic literature regarding Epitalon — telomerase, melatonin, animal lifespan, and intranasal studies in rats — used unmodified AEDG, not N-acetyl Epitalon.

Targeted searches identified chemical registries for N-acetyl Epitalon, but found no comparable peer-reviewed human pharmacokinetic research base or clinical studies on the intranasal acetylated form that would support the reproduction of the biological effects of unmodified Epitalon.

What Evidence is Needed to Compare Nasal Sprays?

A reliable comparison of Epitalon nasal sprays requires data on chemical identity, concentration, purity, formulation, pump performance, delivered dose uniformity, droplet characteristics, stability, microbiological quality, and ideally also pharmacokinetics. Merely comparing the number of milligrams in a bottle or the declared number of sprays does not confirm equivalent exposure or product performance quality.

Two sprays labeled as „Epitalon” can differ significantly even with the same total peptide mass.

A useful scientific comparison should first and foremost confirm that both products contain the same molecule.

This is of particular importance when one product contains unmodified Epitalon and the other contains N-acetyl Epitalon or an amidated derivative.

The next level is analytical quality. Relevant data would include:

• peptide sequence and chemical form;
• chromatographic purity;
• identity confirmation using mass spectrometry;
• determination of the actual peptide content;
• impurities and degradation products;
• pH of the formulation and excipients;
• microbiological testing, if required;
• the calibrated volume delivered per spray;
• dose uniformity;
• droplet size distribution;
• spray pattern and stream geometry;
• stability over the stated shelf life;
• documentation regarding a specific batch.

The FDA’s guidelines on intranasal products illustrate why this level of characterization is important: in the case of sprays, the formulation and the device together influence the delivered dose and the product’s performance.

Even more data are needed for the bioavailability comparison.

Researchers would need to conduct pharmacokinetic studies measuring the concentrations of the intact peptide after administration, preferably including concentration-time curves and a direct comparison of the formulations under controlled conditions.

To compare clinical efficacy, controlled human trials would then be needed.

Without these layers of evidence, claims such as „Product A is stronger because it contains more milligrams,” „N-acetyl spray has higher bioavailability,” or „one press of one brand equals the same exposure as one press of another brand” are not scientifically established.

What Do the Evidence Really Show Regarding Intranasal Epitalon?

Therefore, the overall state of the evidence is best described as preclinical proof of concept for the intranasal route rather than validated human intranasal pharmacology.

Frequently Asked Questions About Epitalon Nasal Spray

Was Epitalon nasal spray studied?

Yes, but mainly in rats, not in humans. In published studies, intranasal Epitalon was used to analyze cortical neuronal activity and the pineal gland’s response to stress. These experiments demonstrate biological activity following intranasal exposure in animals, but do not establish bioavailability in humans, clinical efficacy, or a validated spray protocol. [1–3]

Does Epitalon Nasal Spray Cross the Blood-Brain Barrier?

Researchers using rats chose the intranasal route, among other reasons, because they considered it a potential method for delivery to the central nervous system, and observed rapid responses of cerebral cortex neurons. [1] However, these experiments did not directly measure the passage of intact Epithalon across the blood-brain barrier in humans, so definitive claims regarding delivery to the human brain are not confirmed.

How much Epitalon does one spray deliver?

This cannot be determined based on the bottle size alone. The delivered amount depends on the peptide concentration and the actual volume dispensed by the pump per actuation, while the formulation and device performance may additionally affect dose uniformity. A reliable value per spray therefore requires validated data for the specific product.

Does Nasal Epithalon Have Higher Bioavailability Than Oral?

This has not been demonstrated in a controlled pharmacokinetic study of Epitalon in humans. Nasal administration bypasses direct exposure to a significant portion of the digestive tract, but the amount absorbed through the nasal mucosa remains unknown, so an evidence-based percentage cannot currently be provided nor can the superiority of this route be stated.

Is Nasal Epitalon Better Than Epitalon Injection?

There is no controlled human evidence confirming the superiority of intranasal Epitalon over injection in terms of bioavailability, efficacy, safety, or clinical outcomes that take convenience of use into account. Injection has a larger historical base of animal studies, whereas intranasal Epitalon has been studied mainly in rat neurophysiology and pineal gland experiments.

Is N-Acetyl Epitalon the Same Peptide as Epitalon?

No. Unmodified Epitalon is AEDG with an unmodified N-terminal end, whereas N-acetyl Epitalon contains an additional acetyl group at that end. PubChem and FDA substance registries treat N-acetyl Epitalon as a distinct chemical entity, therefore data concerning unmodified Epitalon cannot be automatically attributed to the acetylated form.

Is N-Acetyl Epitalon Amidate the Same as N-Acetyl Epitalon?

Not necessarily. N-acetyl Epitalon in the free acid form is presented as Ac-AEDG-OH, whereas the amidated derivative additionally changes the C-terminal carboxyl group into an amide, which is Ac-AEDG-NH2. These are different chemical structures and should be distinguished based on their sequence and analytical documentation rather than solely on trade names.

What Can Make One Nasal Spray Different from Another?

Chemical form, concentration, purity, pH, excipients, preservative system, viscosity, pump performance, droplet size, spray pattern, stability, and dose uniformity may matter. FDA guidelines for nasal products clearly recognize that the properties of both the formulation and the device jointly affect product performance.

Limitations of Evidence Regarding the Nasal Spray

The most important limitation is the fact that direct research on intranasal Epitalon is almost exclusively preclinical in nature.

Rat studies are useful because they show that measurable biological responses can occur following intranasal administration of Epitalon. [1–3] However, they do not establish systemic absorption or pharmacokinetics in the central nervous system in humans.

Another limitation is that older experiments were not modern nasal formulation development studies. They did not systematically characterize pump performance, spray geometry, droplet size distribution, nasal deposition site, mucociliary clearance, pharmacokinetics, or human tolerance.

Third, the observed cortical neural responses do not prove a specific delivery pathway. The studies did not directly measure intact Epitalon moving from the nasal cavity to specific brain structures.

Fourthly, commercial sprays may use formulations and devices that differ significantly from the preparations used in historical research.

Fifth, N-acetyl Epitalon introduces an additional evidence gap. Chemical registries confirm that it is a distinct acetylated molecule, but mere presence in a registry is not evidence of human nasal pharmacokinetics, efficacy, safety, or equivalence to AEDG.

Finally, the operation of the device itself can affect exposure. General studies of nasal products show that formulation properties and spray geometry alter the deposition site of material in the nose. As a result, even two chemically identical solutions should not automatically be considered equivalent if they use different pump systems.

Disclaimer

This article is for educational and scientific-informational purposes only and does not constitute medical advice, dosage guidelines, instructions for use of a nasal spray, formulation instructions, or recommendations for the use of Epitalon. Epitalon/Epithalon (AEDG; Ala-Glu-Asp-Gly) remains an experimental peptide, and direct evidence regarding the intranasal route comes mainly from animal studies rather than controlled clinical trials in humans. Human intranasal bioavailability, central nervous system exposure, route-specific safety, optimal formulation, and validated dosing have not been established. N-acetyl Epitalon and amidated derivatives are chemically modified forms and should not be assumed to have the same pharmacology or evidence base as unmodified AEDG.

References

[1] Sibarov, D. A., Vol’nova, A. B., Frolov, D. S., & Nozdrachev, A. D. (2007). Effects of intranasal administration of Epitalon on neuron activity in the rat neocortex. Neuroscience and Behavioral Physiology, 37(9), 889–893. https://doi.org/10.1007/s11055-007-0095-3

[2] Sibarov, D. A., Vol’nova, A. B., Frolov, D. S., & Nosdrachev, A. D. (2006). Intranasal Epitalon infusion modulates neuronal activity in the rat neocortex. Sechenov Physiological Journal of Russia, 92(8), 949–956. https://pubmed.ncbi.nlm.nih.gov/17217245/

[3] Sibarov, D. A., Nozdrachev, A. D., & Khavinson, V. K. (2002). Epitalon influences pineal secretion in stress-exposed rats in the daytime. Neuro Endocrinology Letters, 23(5–6), 452–454. https://pubmed.ncbi.nlm.nih.gov/12500171/

[4] Foo, M. Y., Cheng, Y.-S., Su, W.-C., & Donovan, M. D. (2007). The influence of spray properties on intranasal deposition. Journal of Aerosol Medicine, 20(4), 495–508. https://doi.org/10.1089/jam.2007.0638

[5] Araj, S. K., Brzezik, J., Mądra-Gackowska, K., & Szeleszczuk, Ł. (2025). Overview of Epitalon—Highly bioactive pineal tetrapeptide with promising properties. International Journal of Molecular Sciences, 26(6), 2691. https://doi.org/10.3390/ijms26062691

[6] U.S. Food and Drug Administration. (2002). Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products—Chemistry, Manufacturing, and Controls Documentation: Guidance for Industry.

[7] U.S. Food and Drug Administration. (2003). Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action: Draft Guidance for Industry.

[8] National Center for Biotechnology Information. (2026). PubChem Compound Summary for CID 171390141, N-Acetyl Epitalon.

[9] U.S. Food and Drug Administration. (2026). Global Substance Registration System: N-Acetyl Epitalon, UNII UXR7AF6R4F.